Overview

AMG 334 20160172 Pediatric Migraine PK Study.

Status:
Recruiting
Trial end date:
2022-06-26
Target enrollment:
Participant gender:
Summary
AMG 334 20160172 Pediatric Migraine PK Study.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Erenumab